Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy

J Am Coll Cardiol. 2025 May 27;85(20):1924-1926. doi: 10.1016/j.jacc.2025.04.014.

¹ Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA.
² Department of Cardiology, Smidt Heart Institute, Los Angeles, California, USA.
³ Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.
⁴ Section of Cardiovascular Medicine and Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
⁵ Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: senthil.selvaraj@duke.edu.

No abstract available

Keywords: ATTR-CM; TTR stabilization; acoramidis; all-cause mortality; serum TTR; transthyretin.

Publication types